Phylo, Inc. announced a partnership with Bayer to deploy Biomni Lab, its agentic AI platform, in Bayer’s research labs. The platform lets scientists pull together scientific papers, biomedical data and analysis methods in one place, cutting manual work. It also keeps a record of each step so researchers can see the sources and methods behind any result. Bayer will use Biomni Lab mainly for literature and omics evidence gathering in drug discovery.
Why it matters
Bayer scientists can explore more drug‑discovery hypotheses faster by letting AI handle data gathering and workflow tracking.
